David A Osborne

US Patent:

6792766, Sep 21, 2004

Filed:

Oct 4, 2002

Appl. No.:

10/264645

Inventors:

David Osborne - Garland TX
Brian Chester - Plano TX
Gary R. Scoggins - Dallas TX

Assignee:

Cascade Manufacturing, L.P. - Richardson TX

International Classification:

F25B 2900

US Classification:

62159, 62201, 62175, 236 1 B, 165217

Abstract:

A thermal zone demand controlled air conditioning fan coil unit using dual cascade arranged heat pumps, chilled water, or a combination of chilled water and hot water, with or without back up electric resistance heat strips, and having an air circulation system for circulating air to and from a plurality of thermal zones and including a conditioned air chamber having first and second heat exchange refrigerant coils or direct or reversed cycle water coils being connected in refrigerant circulating relation respectively with the heat pumps, chilled water coil. A plurality of thermal zone blowers conduct conditioned air from the conditioned air chamber to respective thermal zones of a building space. Electronic controller circuitry of the system is coupled for thermal demand control of the heat pumps and the thermal zone blowers for operation of the first heat pump during average thermal load and for operation of both heat pumps during greater thermal load. For chilled or hot water systems, the controller controls operation of thermal zone blowers and motorized valves which control the flow of water to and from the water coils.

US Patent:

20210161870, Jun 3, 2021

Filed:

Feb 5, 2021

Appl. No.:

17/155679

Inventors:

- Westlake Village CA, US
Archie THURSTON - San Diego CA, US
David W. OSBORNE - Fort Collins CO, US

Assignee:

ARCUTIS BIOTHERAPEUTICS, INC. - Westlake Village CA

International Classification:

A61K 31/44
A61K 9/00
A61K 47/10
A61K 9/06
A61K 9/14
A61K 45/06
C09K 15/06

Abstract:

An improved a method of treating a patient having a disorder responsive to PDE-4 inhibition by administering roflumilast. The improvement involves administering the roflumilast topically in a composition having a roflumilast release profile that produces in the patient a flattened plasma concentration time curve and a reduced Cmax relative to oral administration of a PDE4-inhibiting amount of roflumilast. Such disorders include inflammatory disorders such as inflammatory dermatoses, including psoriasis, atopic dermatitis and seborrheic dermatitis. Such disorders also include inflammatory diseases in a variety of organs, especially the lungs (asthma, COPD). Because of reduced side effects with topical administration due to the improved pharmacokinetics (PK) characteristics, it may be possible to provide higher systemic exposures (AUCs) with topical administration, resulting in greater therapeutic efficacy than with the oral route of administration.